Tafluprost
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate | |
Clinical data | |
Trade names | Saflutan, Taflotan, Tapros, Zioptan |
AHFS/Drugs.com | International Drug Names |
Pregnancy cat. | C (US) |
Legal status | ℞-only (US) |
Routes | Topical (eye drops) |
Identifiers | |
CAS number | 209860-87-7 |
ATC code | S01EE05 |
PubChem | CID 6433101 |
ChemSpider | 8044182 |
UNII | 1O6WQ6T7G3 |
ChEBI | CHEBI:66899 |
ChEMBL | CHEMBL1963683 |
Chemical data | |
Formula | C25H34F2O5 |
Mol. mass | 452.531266 g/mol |
SMILES
| |
Tafluprost (trade names Taflotan, marketed by Santen Pharmaceutical Co. and Zioptan, by Merck (U.S.)) is a prostaglandin analogue used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.[1][2]
Taflotan contains 15 µg/ml Tafluprost. Taflotan sine is a preservative-free, single-dose formulation containing 0.3 ml per dose.[3]
References
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2008/2009
- ↑ Santen Home Page
- ↑ Gelbe Liste (in German)
|
|
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.